Study #2015-1040
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Dasatinib and Venetoclax: A Phase II Study
Study Status
Open
Treatment Agent
Dasatinib
Principal Investigator
Hagop Kantarjian
Description
The goal of this clinical research study is to learn if giving half of the recommended FDA approved dose of dasatinib can help to control CML as effectively as the full dose of dasatinib. Researchers also want to learn if combining venetoclax with dasatinib after 3 months of dasatinib alone is helpful in controlling CML compared to dasatinib alone. The safety of the combination will also be studied.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Dasatinib
Treatment Location: Only at MD Anderson
Sponsor: BMS
Study Status
IRB Review and Approval Date: 02/19/2016
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase II
Physician name:
Hagop Kantarjian
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789